Clinical Trial Update: Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) [Phase 2]

View source ↗

Summary

Phase 2 safety and pharmacokinetic study of ATI-50002 in subjects with Alopecia Universalis and Alopecia Totalis has been completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Totalis
• Alopecia Universalis

Drugs mentioned

• ATI-50002 (ATI-50002)

Snippet

Sponsor: Aclaris Therapeutics, Inc. | Conditions: Alopecia Universalis (AU), Alopecia Totalis (AT) | Phase 2 | Status: COMPLETED | Results posted: 2020-07-02